section name header

Information

Synonym/Acronym

TSD (Tay-Sachs disease) testing.

Rationale

To assist in diagnosing Tay-Sachs and Sandhoff disease by identifying a hexosaminidase enzyme deficiency.

Patient Preparation

There are no food, fluid, activity, or medication restrictions unless by medical direction.

Normal Findings

Method: Fluorometry for enzyme assay, polymerase chain reaction (PCR)/primer extension for molecular assay.

Plasma Enzyme Assay Conventional UnitsPlasma Enzyme Assay SI Units (Conventional Units × 0.0167)
Hexosaminidase Total589–955 nmol/hr/mL9.83–15.98 nmol/hr/mL
Hexosaminidase A55%–76% of total hexosaminidase55%–76% of total hexosaminidase
Whole blood leukocyte assay: greater than 62%Molecular assay: Negative for HEXA gene mutationsMolecular assay: Negative for HEXB variants
Methods vary, reference ranges vary; the reference range and interpretive summary provided in the laboratory report should be used to properly evaluate results. Carrier values are approximately half of the expected normal values.

Critical Findings and Potential Interventions

N/A

Overview

Study type: Blood collected in a yellow-top [acid-citrate-dextrose (ACD)] or a red-top tube for hexosaminidase enzyme assay; lavender-top [EDTA], pink-top [K2 EDTA] or yellow-top tube [ACD] for molecular PCR assay; related body system: Reproductive system. The specimen should be transported immediately to the laboratory for processing and analysis.

There are more than 70 lysosomal enzyme disorders. Hexosaminidase is a lysosomal enzyme, the deficiency of which results in accumulation of complex sphingolipids and gangliosides in the brain and spinal cord. The most studied isoenzymes are hexosaminidase A (one alpha and one beta subunit) and hexosaminidase B (two beta subunits); total and A hexosaminidases (plasma, serum, or leukocyte assays) are the studies recommended as first tier testing when investigating suspected Tay-Sachs or Sandhoff disease, both of which are autosomal recessive conditions.

Tay-Sachs disease results from two variants in the HEXA gene and is characterized by a progressive lack of physical and intellectual development that becomes noticeable between 3 and 6 mo of age. Patients who are homozygous for this trait have no hexosaminidase A; signs and symptoms include red spot in the retina, blindness, and muscular weakness. Tay-Sachs disease results in early death, usually between ages 2 to 5 years. Tay-Sachs disease is also known as GM2 gangliosidosis type 1. This enzyme deficiency is most common among Ashkenazi Jews, for whom the incidence is 1 in 3,000 and carrier rate is 1 in 30. An increased carrier frequency is also noted in individuals of Celtic and French-Canadian ancestry.

Sandhoff disease results from two variants in the HEXB gene. Because the HEXB gene is responsible for production of the beta subunit, decreased levels of both hexosaminidase A and B occur and result in accumulation of GM2 ganglioside. Sandoff and Tay-Sachs share many similarities in clinical symptoms and biochemical findings. Sandhoff disease prevalence is not associated with a specific ethnic population. Molecular testing for gene variants can differentiate between Tay-Sachs and Sandoff. Individuals with Sandhoff disease demonstrate low total hexosaminidase levels and a comparatively elevated percent of hexosaminidase A (due to formation of alpha subunits and absence of beta subunits).

Biochemical screening tests are used to measure enzyme activity in serum or in WBCs. Serum screening tests should be chosen for low-risk populations because molecular assays have less than 50% specificity in the low-risk and carrier populations. WBC screening tests should be chosen instead of serum screening tests for women who are pregnant, who are taking oral contraceptives, or who have severe liver or autoimmune disease because of the unreliability of test results in samples from these patients. Negative screening results may be further investigated for the presence of pseudodeficiency mutations, which are non–disease-causing mutations. Molecular testing should be ordered for confirmation when screening results are either inconclusive or indicative of carrier status. Genetic testing by DNA PCR analysis can identify as many as 94% of the gene mutations associated with Tay-Sachs disease in persons with Ashkenazi Jewish heritage, 80% of the mutations in persons with French-Canadian ancestry, and 25% of mutations in non-Jewish Caucasians.

Genetic testing combined with enzyme screening analysis and correlation of clinical information provides the most reliable means of determining carrier status. The American College of Obstetricians and Gynecologists Committee on Genetics recommends that preconceptual or prenatal screening be offered to both persons in a couple if both are of Ashkenazi Jewish, French-Canadian, or Cajun ancestry or to any person with a family history of Tay-Sachs disease. Counseling and written, informed consent are recommended and sometimes required before genetic testing.

Knowledge of genetics assists in identifying those who may benefit from additional education, risk assessment, and counseling. Genetics is the study and identification of genes, genetic mutations, and inheritance. For example, genetics provides some insight into the likelihood of inheriting a medical condition such as Tay-Sachs disease. Some conditions are the result of mutations involving a single gene, whereas other conditions may involve multiple genes and/or multiple chromosomes. Every person receives a copy of the HEXA gene from each parent. If each parent is a carrier, has one normal and one abnormal or mutated HEXA gene, the baby has a 25% chance of developing Tay-Sachs disease because the possible combinations are 25% normal (a normal gene provided from each parent), 50% normal/carrier (a normal gene from the father and an abnormal gene from the mother or a normal gene from the mother and an abnormal gene from the father), and 25% abnormal (an abnormal gene provided from each parent). Babies who inherit a normal and abnormal copy of the HEXA gene are also considered carriers because they provide the potential for transmitting the condition to the next generation. Further information regarding inheritance of genes can be found in the study titled “Genetic Testing.”

Indications

Interfering Factors

Contraindications

Parents who are not emotionally capable of understanding the test results and managing the ramifications of the test results.

Factors That May Alter the Results of the Study

  • Drugs and other substances that may increase hexosaminidase levels include ethanol, isoniazid, oral contraceptives, and rifampin.
  • The serum specimen hexosaminidase assay should not be performed on women who are pregnant or who are taking oral contraceptives. Increases in enzyme activity during pregnancy occur in carriers and noncarriers of the Tay-Sachs gene. Enzyme activity is also notably increased in women taking oral contraceptives regardless of carrier status.

Potential Medical Diagnosis: Clinical Significance of Results

Increased In

Alterations in lysosomal enzymes metabolism are associated with various conditions.

Decreased In

  • Total
    • Sandhoff disease (inherited disorder of enzyme metabolism lacking both essential enzymes for metabolizing gangliosides)
  • Hexosaminidase A
    • Tay-Sachs disease (inherited disorder of enzyme metabolism lacking only the hexosaminidase A enzyme for metabolizing gangliosides)
    • Sandhoff disease (inherited disorder of enzyme metabolism lacking both essential enzymes for metabolizing gangliosides)
  • Hexosaminidase B
    • Sandhoff disease

Nursing Implications, Nursing Process, Clinical Judgement

Before the Study: Planning and Implementation

Teaching the Patient What to Expect

  • Discuss how this test can assist in diagnosing or identifying carrier status for Tay-Sachs disease.
  • Explain that a blood sample is needed for the test.

After the Study: Implementation & Evaluation Potential Nursing Actions

Treatment Considerations

  • Encourage the family to seek genetic counseling if results are abnormal.
  • Discuss feelings the mother and father may experience (e.g., guilt, depression, anger) if abnormalities are detected.
  • Discuss disease symptoms that parents should be aware of: seizures, hearing loss, muscle weakness, motor skill deficits (sitting, crawling, rolling over), vision loss, exaggerated startle with loud noise, difficulty swallowing, and red spots in the eyes.
  • Discuss treatment alternatives designed to support the infant’s deficits: feeding tubes, medications, physical therapy, and respiratory therapy.

Clinical Judgement

  • Consider which tertiary care therapeutics will provide the best ongoing symptomatic support.

Follow-Up and Desired Outcomes

  • Acknowledges contact information provided for counseling services and for the National Tay-Sachs and Allied Diseases Association (www.ntsad.org).